» Articles » PMID: 33072997

Incidence of Glucose-6-Phosphate Dehydrogenase Deficiency Among Swedish Newborn Infants

Overview
Date 2020 Oct 19
PMID 33072997
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Sweden has 10.2 million inhabitants and more than 2.4 million have a foreign background. A substantial number of immigrants come from countries where glucose-6-phosphate dehydrogenase deficiency (G6PDD) is frequent. The total birth rate annually in Sweden is approximately 117,000 and newborn screening is centralized to one laboratory. We determined glucose-6-phosphate dehydrogenase (G6PD) activity in 10,098 dried blood spot samples (DBS) from the whole country with a fluorometric assay (LabSystems Diagnostics Oy, Finland). The first 5451 samples were anonymised and run as singletons, whilst the following 4647 samples were coded. Enzyme activity ≤40% of the mean of the day was found in 58 samples (1/170) and among these, 29 had activities ≤10% (1/350). Twenty-nine samples with residual activities between 2-39% in the coded cohort were subjected to Sanger sequencing. Disease-causing variants were identified in 26 out of 29 infants, of which six were girls. In three patients, we did not find any disease-causing variants, although two patients were hemizygous for the known polymorphisms c.1311T>C and c.1365-13C>T. The most common disease-causing variant found in 15 of the 29 samples (12 hemizygotes, two heterozygotes, one homozygote) was the Mediterranean mutation, c.563C>T (p.(Ser188Phe)) in exon 6. G6PDD is thus a surprisingly prevalent disorder in Sweden.

Citing Articles

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020-2023).

Therrell B, Padilla C, Borrajo G, Khneisser I, Schielen P, Knight-Madden J Int J Neonatal Screen. 2024; 10(2).

PMID: 38920845 PMC: 11203842. DOI: 10.3390/ijns10020038.


The Controversial Role of Glucose-6-Phosphate Dehydrogenase Deficiency on Cardiovascular Disease: A Narrative Review.

Dore M, Parodi G, Portoghese M, Pes G Oxid Med Cell Longev. 2021; 2021:5529256.

PMID: 34007401 PMC: 8110402. DOI: 10.1155/2021/5529256.


Genetic spectrum and clinical early natural history of glucose-6-phosphate dehydrogenase deficiency in Mexican children detected through newborn screening.

Vela-Amieva M, Alcantara-Ortigoza M, Gonzalez-Del Angel A, Belmont-Martinez L, Lopez-Candiani C, Ibarra-Gonzalez I Orphanet J Rare Dis. 2021; 16(1):103.

PMID: 33637102 PMC: 7913327. DOI: 10.1186/s13023-021-01693-9.

References
1.
Nkhoma E, Poole C, Vannappagari V, Hall S, Beutler E . The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009; 42(3):267-78. DOI: 10.1016/j.bcmd.2008.12.005. View

2.
Alken J, Hakansson S, Ekeus C, Gustafson P, Norman M . Rates of Extreme Neonatal Hyperbilirubinemia and Kernicterus in Children and Adherence to National Guidelines for Screening, Diagnosis, and Treatment in Sweden. JAMA Netw Open. 2019; 2(3):e190858. PMC: 6583272. DOI: 10.1001/jamanetworkopen.2019.0858. View

3.
Mason P, Bautista J, Gilsanz F . G6PD deficiency: the genotype-phenotype association. Blood Rev. 2007; 21(5):267-83. DOI: 10.1016/j.blre.2007.05.002. View

4.
Stanton R . Glucose-6-phosphate dehydrogenase, NADPH, and cell survival. IUBMB Life. 2012; 64(5):362-9. PMC: 3325335. DOI: 10.1002/iub.1017. View

5.
La Vieille S, Lefebvre D, Khalid A, Decan M, Godefroy S . Dietary restrictions for people with glucose-6-phosphate dehydrogenase deficiency. Nutr Rev. 2018; 77(2):96-106. DOI: 10.1093/nutrit/nuy053. View